Lexicon Pharmaceuticals Q1 EPS $(0.07) Beats $(0.10) Estimate, Sales $1.26M Miss $1.41M Estimate

Author: Benzinga Newsdesk | May 13, 2025 04:09pm
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 65 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $1.26 million which missed the analyst consensus estimate of $1.41 million by 10.65 percent. This is a 11.68 percent increase over sales of $1.13 million the same period last year.

Posted In: LXRX